Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

HNF1A-AS1: A Tumor-associated Long Non-coding RNA

Author(s): Yuling Liu, Fangnan Zhao, Fangshun Tan, Lu Tang, Zhuoying Du, Jie Mou, Gang Zhou* and Chengfu Yuan*

Volume 28, Issue 21, 2022

Published on: 06 July, 2022

Page: [1720 - 1729] Pages: 10

DOI: 10.2174/1381612828666220520113846

Price: $65

Abstract

Background: Hepatocyte nuclear factor 1 homeobox A antisense RNA 1 (HNF1A-AS1) is a Long non-coding RNA (LncRNA) that participates in the occurrence and development of lots of tumors and is supposed to be a new biomarker. The text aims to illustrate the biological effect, specific mechanism and clinical significance of HNF1A-AS1 in various tumors.

Methods: Via consulting the literature, analyze and summarize the relationship between HNF1A-AS1 and all kinds of tumors and the specific mechanism.

Results: This is a review paper about the tumor-associated long non-coding RNA HNF1A-AS1. Many researches show that LncRNA HNF1A-AS1 is related to the development of tumorous tumors. Its expression is up-regulated in numerous tumors, such as oral squamous cell carcinoma, hepatocellular carcinoma, breast cancer, osteosarcoma, lung cancer, cervical cancer, bladder cancer, colon cancer, colorectal cancer, oesophageal adenocarcinoma and laryngeal squamous cell carcinoma. However, HNF1A-AS1 is down-regulated in gastroenteropancreatic, neuroendocrine neoplasms, oral squamous cell carcinoma. Furthermore, HNF1A-AS1 can affect tumor proliferation, invasion, migration and apoptosis by targeting some microRNAs-miR-661 and miR-124. HNF1A-AS1 can also influence the development of tumors by regulating EMT.

Conclusion: These studies show that LncRNA-HNF1A-AS1 is closely related to the occurrence development of numerous cancers. Through various molecular mechanisms to regulate tumor growth, HNF1A-AS1 can possibly become the new biological biomarker and therapeutic target for many kinds of tumors.

Keywords: Molecular mechanism, HNF1A-AS1, adenocarcinoma, long non-coding RNA, therapeutic target, neuroendocrine neoplasms.

[1]
Luo X, Wei J, Yang FL, et al. Exosomal lncRNA HNF1A-AS1 affects cisplatin resistance in cervical cancer cells through regulating microRNA-34b/TUFT1 axis. Cancer Cell Int 2019; 19(1): 323.
[http://dx.doi.org/10.1186/s12935-019-1042-4 ] [PMID: 31827397]
[2]
Liu Z, Li H, Fan S, Lin H, Lian W. STAT3-induced upregulation of long noncoding RNA HNF1A-AS1 promotes the progression of oral squamous cell carcinoma via activating Notch signaling pathway. Cancer Biol Ther 2019; 20(4): 444-53.
[http://dx.doi.org/10.1080/15384047.2018.1529119 ] [PMID: 30404566]
[3]
Yuen VW, Wong CC. Hypoxia-inducible factors and innate immunity in liver cancer. J Clin Invest 2020; 130(10): 5052-62.
[http://dx.doi.org/10.1172/JCI137553 ] [PMID: 32750043]
[4]
Wang C, Mou L, Chai HX, Wang F, Yin YZ, Zhang XY. Long non-coding RNA HNF1A-AS1 promotes hepatocellular carcinoma cell proliferation by repressing NKD1 and P21 expression. Biomed Pharmacother 2017; 89: 926-32.
[http://dx.doi.org/10.1016/j.biopha.2017.01.031 ] [PMID: 28292020]
[5]
Liu Z, Wei X, Zhang A, Li C, Bai J, Dong J. Long non-coding RNA HNF1A-AS1 functioned as an oncogene and autophagy promoter in hepatocellular carcinoma through sponging hsa-miR-30b-5p. Biochem Biophys Res Commun 2016; 473(4): 1268-75.
[http://dx.doi.org/10.1016/j.bbrc.2016.04.054 ] [PMID: 27084450]
[6]
Ding CH, Yin C, Chen SJ, et al. The HNF1α-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1. Mol Cancer 2018; 17(1): 63.
[http://dx.doi.org/10.1186/s12943-018-0813-1 ] [PMID: 29466992]
[7]
Meng Q, Wang L, Lv Y, Wu J, Shi W. Deletion of HNF1A-AS1 suppresses the malignant phenotypes of breast cancer cells in vitro and in vivo through targeting miRNA-20a-5p/TRIM32 Axis. Cancer Biother Radiopharm 2021; 36(1): 23-35.
[http://dx.doi.org/10.1089/cbr.2019.3168 ] [PMID: 32319789]
[8]
Li Y, Liu L, Lv Y, et al. Silencing long non-coding RNA HNF1A-AS1 inhibits growth and resistance to TAM of breast cancer cells via the microRNA-363/SERTAD3 axis. J Drug Target 2021; 29(7): 742-53.
[http://dx.doi.org/10.1080/1061186X.2021.1878362 ] [PMID: 33472456]
[9]
Yang J, Niu H, Chen X. GATA1-activated HNF1A-AS1 facilitates the progression of triple-negative breast cancer via sponging miR-32-5p to upregulate RNF38. Cancer Manag Res 2021; 13: 1357-69.
[http://dx.doi.org/10.2147/CMAR.S274204 ] [PMID: 33603481]
[10]
Dang Y, Lan F, Ouyang X, et al. Expression and clinical significance of long non-coding RNA HNF1A-AS1 in human gastric cancer. World J Surg Oncol 2015; 13(1): 302.
[http://dx.doi.org/10.1186/s12957-015-0706-3 ] [PMID: 26472090]
[11]
Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: A comprehensive review of current and future treatment strategies. Cancer Metastasis Rev 2020; 39(4): 1179-203.
[http://dx.doi.org/10.1007/s10555-020-09925-3 ] [PMID: 32894370]
[12]
Liu HT, Liu S, Liu L, Ma RR, Gao P. EGR1-Mediated transcription of lncRNA-HNF1A-AS1 promotes cell-cycle progression in gastric cancer. Cancer Res 2018; 78(20): 5877-90.
[http://dx.doi.org/10.1158/0008-5472.CAN-18-1011 ] [PMID: 30185552]
[13]
Liu HT, Ma RR, Lv BB, et al. LncRNA-HNF1A-AS1 functions as a competing endogenous RNA to activate PI3K/AKT signalling pathway by sponging miR-30b-3p in gastric cancer. Br J Cancer 2020; 122(12): 1825-36.
[http://dx.doi.org/10.1038/s41416-020-0836-4 ] [PMID: 32336754]
[14]
Jiang L, Zhang Y, Su P, et al. Long non-coding RNA HNF1A-AS1 induces 5-FU resistance of gastric cancer through miR-30b-5p/EIF5A2 pathway. Transl Oncol 2022; 18: 101351.
[http://dx.doi.org/10.1016/j.tranon.2022.101351 ] [PMID: 35092904]
[15]
Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2018; 68(6): 471-87.
[http://dx.doi.org/10.3322/caac.21493 ] [PMID: 30295930]
[16]
Ahmed M. Gastrointestinal neuroendocrine tumors in 2020. World J Gastrointest Oncol 2020; 12(8): 791-807.
[http://dx.doi.org/10.4251/wjgo.v12.i8.791 ] [PMID: 32879660]
[17]
Xue J, Bai J, Long Q, et al. TCF-3-mediated transcription of lncRNA HNF1A-AS1 targeting oncostatin M expression inhibits epithelial-mesenchymal transition via TGFβ signaling in gastroenteropancreatic neuroendocrine neoplasms. Aging (Albany NY) 2021; 13(10): 14065-77.
[http://dx.doi.org/10.18632/aging.203024 ] [PMID: 34037532]
[18]
Wang Z, Liu L, Du Y, Mi Y, Wang L. The HNF1A-AS1/miR-92a-3p axis affects the radiosensitivity of non-small cell lung cancer by competitively regulating the JNK pathway. Cell Biol Toxicol 2021; 37(5): 715-29.
[http://dx.doi.org/10.1007/s10565-021-09595-z ] [PMID: 33755848]
[19]
Zhang G, An X, Zhao H, Zhang Q, Zhao H. Long non-coding RNA HNF1A-AS1 promotes cell proliferation and invasion via regulating miR-17-5p in non-small cell lung cancer. Biomed Pharmacother 2018; 98: 594-9.
[http://dx.doi.org/10.1016/j.biopha.2017.12.080 ] [PMID: 29289833]
[20]
Liu L, Chen Y, Li Q, Duan P. lncRNA HNF1A-AS1 modulates non-small cell lung cancer progression by targeting miR-149-5p/Cdk6. J Cell Biochem 2019; 120(11): 18736-50.
[http://dx.doi.org/10.1002/jcb.29186 ] [PMID: 31243821]
[21]
Wu Y, Liu H, Shi X, Yao Y, Yang W, Song Y. The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. Oncotarget 2015; 6(11): 9160-72.
[http://dx.doi.org/10.18632/oncotarget.3247 ] [PMID: 25863539]
[22]
Cai L, Lv J, Zhang Y, Li J, Wang Y, Yang H. The lncRNA HNF1A-AS1 is a negative prognostic factor and promotes tumorigenesis in osteosarcoma. J Cell Mol Med 2017; 21(11): 2654-62.
[http://dx.doi.org/10.1111/jcmm.12944 ] [PMID: 28866868]
[23]
Zhang X, Xiong Y, Tang F, Bian Y, Chen Y, Zhang F. Long noncoding RNA HNF1A-AS1 indicates a poor prognosis of colorectal cancer and promotes carcinogenesis via activation of the Wnt/β-catenin signaling pathway. Biomed Pharmacother 2017; 96: 877-83.
[http://dx.doi.org/10.1016/j.biopha.2017.10.033 ] [PMID: 29145164]
[24]
Lou P, Ding T, Zhan X. Long noncoding RNA HNF1A-AS1 regulates osteosarcoma Advancement through modulating the miR-32-5p/HMGB1 axis. Cancer Biother Radiopharm 2021; 36(4): 371-81.
[http://dx.doi.org/10.1089/cbr.2019.3486 ] [PMID: 32706998]
[25]
Revathidevi S, Murugan AK, Nakaoka H, Inoue I, Munirajan AK. APOBEC: A molecular driver in cervical cancer pathogenesis. Cancer Lett 2021; 496: 104-16.
[http://dx.doi.org/10.1016/j.canlet.2020.10.004 ] [PMID: 33038491]
[26]
Adiga D, Eswaran S, Pandey D, Sharan K, Kabekkodu SP. Molecular landscape of recurrent cervical cancer. Crit Rev Oncol Hematol 2021; 157: 103178.
[http://dx.doi.org/10.1016/j.critrevonc.2020.103178 ] [PMID: 33279812]
[27]
Xu J, Zou J, Wu L, Lu W. Transcriptome analysis uncovers the diagnostic value of miR-192-5p/HNF1A-AS1/VIL1 panel in cervical adenocarcinoma. Sci Rep 2020; 10(1): 16584.
[http://dx.doi.org/10.1038/s41598-020-73523-0 ] [PMID: 33024199]
[28]
Feng Z, Wang B. Long non-coding RNA HNF1A-AS1 promotes cell viability and migration in human bladder cancer. Oncol Lett 2018; 15(4): 4535-40.
[http://dx.doi.org/10.3892/ol.2018.7878 ] [PMID: 29541223]
[29]
Chamie K, Litwin MS, Bassett JC, et al. Recurrence of high-risk bladder cancer: A population-based analysis. Cancer 2013; 119(17): 3219-27.
[http://dx.doi.org/10.1002/cncr.28147 ] [PMID: 23737352]
[30]
Zhan Y, Li Y, Guan B, et al. Long non-coding RNA HNF1A-AS1 promotes proliferation and suppresses apoptosis of bladder cancer cells through upregulating Bcl-2. Oncotarget 2017; 8(44): 76656-65.
[http://dx.doi.org/10.18632/oncotarget.20795 ] [PMID: 29100339]
[31]
Azvolinsky A. Colorectal cancer: To stack or sequence therapy? J Natl Cancer Inst 2015; 107(5): 107.
[http://dx.doi.org/10.1093/jnci/djv138 ] [PMID: 25957442]
[32]
Fang C, Qiu S, Sun F, et al. Long non-coding RNA HNF1A-AS1 mediated repression of miR-34a/SIRT1/p53 feedback loop promotes the metastatic progression of colon cancer by functioning as a competing endogenous RNA. Cancer Lett 2017; 410: 50-62.
[http://dx.doi.org/10.1016/j.canlet.2017.09.012 ] [PMID: 28943452]
[33]
Wu J, Meng X, Jia Y, et al. Long non-coding RNA HNF1A-AS1 upregulates OTX1 to enhance angiogenesis in colon cancer via the binding of transcription factor PBX3. Exp Cell Res 2020; 393(2): 112025.
[http://dx.doi.org/10.1016/j.yexcr.2020.112025 ] [PMID: 32325080]
[34]
Harada K, Rogers JE, Iwatsuki M, Yamashita K, Baba H, Ajani JA. Recent advances in treating oesophageal cancer. F1000 Res 2020; 9: 9.
[http://dx.doi.org/10.12688/f1000research.22926.1 ] [PMID: 33042518]
[35]
Karstens KF, Stüben BO, Reeh M. Oesophageal adenocarcinomas: where do we stand today? Cancers (Basel) 2020; 13(1): 13.
[http://dx.doi.org/10.3390/cancers13010109 ] [PMID: 33396388]
[36]
Yang X, Song JH, Cheng Y, et al. Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells. Gut 2014; 63(6): 881-90.
[http://dx.doi.org/10.1136/gutjnl-2013-305266 ] [PMID: 24000294]
[37]
Johdi NA, Sukor NF. Colorectal cancer immunotherapy: options and strategies. Front Immunol 2020; 11: 1624.
[http://dx.doi.org/10.3389/fimmu.2020.01624 ] [PMID: 33042104]
[38]
Long J, He Q, Yin Y, Lei X, Li Z, Zhu W. The effect of miRNA and autophagy on colorectal cancer. Cell Prolif 2020; 53(10): e12900.
[http://dx.doi.org/10.1111/cpr.12900 ] [PMID: 32914514]
[39]
Guo X, Zhang Y, Liu L, Yang W, Zhang Q. HNF1A-AS1 regulates cell migration, invasion and glycolysis via modulating miR-124/MYO6 in colorectal cancer cells. OncoTargets Ther 2020; 13: 1507-18.
[http://dx.doi.org/10.2147/OTT.S231249 ] [PMID: 32110048]
[40]
Shi Y, Zhang Q, Xie M, et al. Aberrant methylation-mediated decrease of lncRNA HNF1A-AS1 contributes to malignant progression of laryngeal squamous cell carcinoma via EMT. Oncol Rep 2020; 44(6): 2503-16.
[http://dx.doi.org/10.3892/or.2020.7823 ] [PMID: 33125127]
[41]
Wu J, Li R, Li L, et al. MYC-activated lncRNA HNF1A-AS1 overexpression facilitates glioma progression via cooperating with miR-32-5p/SOX4 axis. Cancer Med 2020; 9(17): 6387-98.
[http://dx.doi.org/10.1002/cam4.3186 ] [PMID: 33448691]
[42]
Bi Y, Mao Y, Su Z, Du J, Ye L, Xu F. Long noncoding RNA HNF1A-AS1 regulates proliferation and apoptosis of glioma through activation of the JNK signaling pathway via miR-363-3p/MAP2K4. J Cell Physiol 2021; 236(2): 1068-82.
[http://dx.doi.org/10.1002/jcp.29916 ] [PMID: 32779194]
[43]
Ma C, Wang H, Zong G, et al. EGR1 modulated LncRNA HNF1A-AS1 drives glioblastoma progression via miR-22-3p/ENO1 axis. Cell Death Discov 2021; 7(1): 350.
[http://dx.doi.org/10.1038/s41420-021-00734-3 ] [PMID: 34772911]
[44]
Huang H, Fu S, Liu D. Detection and analysis of the hedgehog signaling pathway-related long non-coding RNA (lncRNA) expression profiles in keloid. Med Sci Monit 2018; 24: 9032-44.
[http://dx.doi.org/10.12659/MSM.911159 ] [PMID: 30543583]
[45]
Bahrami T, Taheri M, Omrani MD, Karimipoor M. Associations between genomic variants in lncRNA-TRPM2-AS and lncRNA-HNF1A-AS1 genes and risk of multiple sclerosis. J Mol Neurosci 2020; 70(7): 1050-5.
[http://dx.doi.org/10.1007/s12031-020-01504-z ] [PMID: 32100228]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy